Atea Pharmaceuticals, Inc. (AVIR) shareholders
Close on Nov 17, 2026Market cap $317.61MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 11,950,772 | 15.00% | 13G (passive) amendment | Mar 31, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (11.60%) | 9,095,680 | 11.60% | 13G (passive) amendment | Nov 28, 2025 |
| Jean-Pierre Sommadossi Joint filing with JPM Partners LLC (6.90%) | 8,876,453 | 10.10% | 13G (passive) amendment | Mar 31, 2025 |
| Leonard Braden Michael Joint filing with BML Investment Partners, L.P. (9.60%) | 7,810,000 | 9.90% | 13G (passive) | Dec 31, 2025 |
| BlackRock, Inc. | 6,082,350 | 7.10% | 13G (passive) amendment | Mar 31, 2025 |
| Kevin Tang Joint filing with Tang Capital Management, LLC (6.00%) | 4,814,700 | 6.00% | 13G (passive) | Oct 6, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AVIR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 12,004,064 | 14.97% | $55.82M | +53,292 | 0.00% |
| BlackRock, Inc. | 8,720,077 | 10.87% | $40.55M | +284,640 | 0.00% |
| BML Capital Management, LLC | 6,952,330 | 8.67% | $32.33M | −106,327 | 18.36% |
| Tang Capital Management LLC | 4,814,700 | 6.00% | $22.39M | – | 1.02% |
| Vanguard Capital Management LLC | 2,964,862 | 3.70% | $13.79M | −281,262 | 0.00% |
| Bain Capital Life Sciences Investors, LLC | 2,075,639 | 2.59% | $9.65M | −284,999 | 0.57% |
| Acadian Asset Management LLC | 2,035,192 | 2.54% | $9.46M | +452,375 | 0.01% |
| Geode Capital Management, LLC | 1,958,435 | 2.44% | $9.11M | +210,729 | 0.00% |
| State Street Corp | 1,652,399 | 2.06% | $7.68M | −42,236 | 0.00% |
| Two Sigma Investments, LP | 1,506,697 | 1.88% | $7.01M | −357,467 | 0.01% |
| Dimensional Fund Advisors LP | 1,299,515 | 1.62% | $6.04M | +44,031 | 0.00% |
| Renaissance Technologies LLC | 1,131,200 | 1.41% | $5.26M | −35,200 | 0.01% |
| Rosalind Advisors, Inc. | 1,070,550 | 1.33% | $4.98M | −101,305 | 1.85% |
| JPMorgan Chase & Co | 945,918 | 1.18% | $4.36M | +5,761 | 0.00% |
| Northern Trust Corp | 755,239 | 0.94% | $3.51M | +170,214 | 0.00% |
| Morgan Stanley | 719,514 | 0.90% | $3.35M | −11,506 | 0.00% |
| Vanguard Portfolio Management LLC | 630,185 | 0.79% | $2.93M | +72,606 | 0.00% |
| Charles Schwab Investment Management Inc | 610,607 | 0.76% | $2.84M | +13,898 | 0.00% |
| Goldman Sachs Group Inc | 530,856 | 0.66% | $2.47M | −57,607 | 0.00% |
| Vanguard Fiduciary Trust Co | 469,801 | 0.59% | $2.18M | −14,904 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 125 | 59M | 74.1% | 19 / 46 | 38 / 20 | 3M | 3M |
| Q1 2026 | 127 | 60M | 74.9% | 27 / 38 | 40 / 10 | 11M | 4M |
| Q4 2025 | 111 | 57M | 71.4% | 11 / 31 | 43 / 12 | 7M | 3M |
| Q3 2025 | 115 | 54M | 67.1% | 15 / 34 | 38 / 6 | 3M | 2M |
| Q2 2025 | 106 | 53M | 65.7% | 13 / 36 | 28 / 10 | 2M | 2M |
| Q1 2025 | 103 | 53M | 66.0% | 9 / 37 | 36 / 11 | 2M | 5M |
| Q4 2024 | 106 | 56M | 70.2% | 14 / 38 | 32 / 16 | 3M | 5M |
| Q3 2024 | 108 | 58M | 72.3% | 15 / 40 | 29 / 11 | 11M | 1M |
| Q2 2024 | 105 | 57M | 70.7% | 13 / 36 | 37 / 21 | 5M | 3M |
| Q1 2024 | 113 | 55M | 68.9% | 19 / 35 | 38 / 14 | 3M | 4M |
| Q4 2023 | 108 | 56M | 69.3% | 11 / 45 | 30 / 21 | 5M | 5M |
| Q3 2023 | 119 | 57M | 70.9% | 6 / 44 | 42 / 20 | 6M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
148 funds held AVIR in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AVIR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 3,102,958 | 3.87% | $14.49M | 0.01% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,032,268 | 2.53% | $9.45M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,835,401 | 2.29% | $8.53M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 1,217,814 | 1.52% | $5.69M | 0.02% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 865,318 | 1.08% | $4.02M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 771,325 | 0.96% | $3.63M | 0.01% | Jul 31, 2026 |
| Fidelity Series Growth Company Fund | 733,900 | 0.92% | $3.43M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 669,481 | 0.83% | $3.11M | 0.02% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 613,370 | 0.76% | $2.86M | 0.05% | May 29, 2026 |
| iShares Biotechnology ETF | 437,948 | 0.55% | $2.04M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 358,829 | 0.45% | $1.68M | 0.01% | May 31, 2026 |
| U.S. Small Cap Portfolio | 349,976 | 0.44% | $1.64M | 0.01% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 345,893 | 0.43% | $1.62M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 313,724 | 0.39% | $1.47M | 0.00% | May 31, 2026 |
| Select Biotechnology Portfolio | 287,662 | 0.36% | $1.34M | 0.03% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jean-Pierre Sommadossi | President, CEO, and Chairman, Director | 6,633,855 | 8.27% | Feb 3, 2026 |
| Andrea Corcoran | See Remarks | 823,576 | 1.03% | Mar 13, 2026 |
| Janet MJ Hammond | Chief Development Officer | 127,665 | 0.16% | Feb 3, 2026 |
| Wayne Foster | EVP, Chief Accounting Officer | 91,461 | 0.11% | Feb 3, 2026 |
| Maria Arantxa Horga | Chief Medical Officer | 112,159 | 0.14% | Feb 3, 2026 |
| John Vavricka | Chief Commercial Officer | 176,672 | 0.22% | Feb 3, 2026 |
| Jerome M. Adams | Director | 92,350 | 0.12% | Jun 23, 2026 |
| Arthur S. Kirsch | Director | 45,710 | 0.06% | Jun 23, 2026 |
| Howard Berman | Director | – | – | Jun 23, 2026 |
| Franklin M. Berger | Director | 536,097 | 0.67% | Jun 23, 2026 |
| Barbara Gayle Duncan | Director | 92,350 | 0.12% | Jun 23, 2026 |
| Bruno Lucidi | Director | 142,350 | 0.18% | Jun 23, 2026 |
| Bruce Polsky | Director | 124,806 | 0.16% | Jun 23, 2026 |
| Polly A. Murphy | Director | 133,040 | 0.17% | Jun 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Barbara Gayle Duncan Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 92,350 |
| Franklin M. Berger Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 536,097 |
| Jerome M. Adams Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 92,350 |
| Bruno Lucidi Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 142,350 |
| Polly A. Murphy Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 121,745 |
| Bruce Polsky Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 124,806 |
| Polly A. Murphy Director | May 18, 2026 | Buy | +6,100 | $4.17 | $25.44K | 92,145 |
| Andrea Corcoran See Remarks | Mar 11, 2026 | Option exercise | +60,000 | $1.24 | $74.40K | 823,576 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Feb 3, 2026 | Option exercise | +300,000 | $1.24 | $372.00K | 767,830 |
| John Vavricka Chief Commercial Officer | Jan 31, 2026 | Option exercise | +42,083 | – | – | 94,164 |
| John Vavricka Chief Commercial Officer | Jan 31, 2026 | Tax withholding | −11,570 | $4.24 | $49.06K | 82,594 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2026 | Option exercise | +272,983 | – | – | 573,923 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2026 | Tax withholding | −106,093 | $4.24 | $449.83K | 467,830 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2026 | Option exercise | +51,283 | – | – | 112,159 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2026 | Tax withholding | −16,073 | $4.24 | $68.15K | 96,086 |
| Andrea Corcoran See Remarks | Jan 31, 2026 | Tax withholding | −16,104 | $4.24 | $68.28K | 763,576 |
| Andrea Corcoran See Remarks | Jan 31, 2026 | Option exercise | +54,866 | – | – | 779,680 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2026 | Tax withholding | −14,136 | $4.24 | $59.94K | 127,665 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2026 | Option exercise | +58,050 | – | – | 141,801 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2026 | Option exercise | +41,333 | – | – | 91,461 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2026 | Tax withholding | −12,132 | $4.24 | $51.44K | 79,329 |
| Jerome M. Adams Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 62,750 |
| Bruce Polsky Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 95,206 |
| Barbara Gayle Duncan Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 62,750 |
| Franklin M. Berger Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 506,497 |
| Polly A. Murphy Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 86,045 |
| Bruno Lucidi Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 112,750 |
| Polly A. Murphy Director | May 18, 2025 | Buy | +6,100 | $4.17 | $25.44K | 92,145 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2025 | Tax withholding | −88,601 | $3.06 | $271.12K | 300,940 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2025 | Option exercise | +173,467 | – | – | 290,024 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2025 | Award | +99,517 | – | – | 389,541 |
| John Vavricka Chief Commercial Officer | Jan 31, 2025 | Tax withholding | −11,517 | $3.06 | $35.24K | 52,081 |
| John Vavricka Chief Commercial Officer | Jan 31, 2025 | Option exercise | +33,333 | – | – | 54,848 |
| John Vavricka Chief Commercial Officer | Jan 31, 2025 | Award | +8,750 | – | – | 63,598 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2025 | Award | +11,250 | – | – | 95,522 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2025 | Tax withholding | −14,134 | $3.06 | $43.25K | 81,388 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2025 | Option exercise | +46,800 | – | – | 84,272 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2025 | Tax withholding | −12,062 | $3.06 | $36.91K | 50,128 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2025 | Award | +8,000 | – | – | 62,190 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2025 | Option exercise | +33,333 | – | – | 54,190 |
| Andrea Corcoran See Remarks | Jan 31, 2025 | Option exercise | +44,367 | – | – | 722,909 |
| Andrea Corcoran See Remarks | Jan 31, 2025 | Award | +10,500 | – | – | 733,409 |
| Andrea Corcoran See Remarks | Jan 31, 2025 | Tax withholding | −16,102 | $3.06 | $49.27K | 717,307 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2025 | Option exercise | +41,533 | – | – | 67,197 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2025 | Tax withholding | −16,071 | $3.06 | $49.18K | 60,876 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2025 | Award | +9,750 | – | – | 76,947 |
| Franklin M. Berger Director | Jan 16, 2025 | Buy | −10,000 | $3.36 | $33.60K | 476,897 |
| Franklin M. Berger Director | Jan 16, 2025 | Buy | +10,000 | $3.36 | $33.60K | 476,897 |
| Franklin M. Berger Director | Jan 15, 2025 | Buy | −15,000 | $3.19 | $47.85K | 466,897 |
| Franklin M. Berger Director | Jan 15, 2025 | Buy | +15,000 | $3.19 | $47.85K | 466,897 |
| Franklin M. Berger Director | Dec 10, 2024 | Sale | −359,606 | $2.85 | $1.02M | 451,897 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Sep 19, 2024 | Sale(10b5-1 plan) | −1,841 | $4.00 | $7.36K | 5,866,025 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Sep 18, 2024 | Sale(10b5-1 plan) | −22,187 | $4.03 | $89.41K | 5,867,866 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Sep 17, 2024 | Sale(10b5-1 plan) | −33,941 | $4.05 | $137.46K | 5,890,053 |
| Bruce Polsky Director | Jun 20, 2024 | Sale | −17,544 | $3.49 | $61.23K | 65,606 |
| Polly A. Murphy Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 56,445 |
| Bruno Lucidi Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 83,150 |
| Bruce Polsky Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 83,150 |
| Franklin M. Berger Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 811,503 |
| Barbara Gayle Duncan Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 33,150 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Atea Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,237 shares on Sep 18, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Franklin M. Berger Lead Independent Director | Dec 10, 2024 | 359,606 | $1.02M | Dec 10, 2024 | Investment |
| JPM Partners LLC Affiliate | Sep 19, 2024 | 1,841 | $7.37K | Sep 19, 2024 | Founder Shares |
| JPM Partners LLC Affiliate | Sep 18, 2024 | 22,187 | $89.47K | Sep 18, 2024 | Founder Shares |
| JPM Partners LLC Affiliate | Sep 17, 2024 | 33,941 | $137.32K | Sep 17, 2024 | Founder Shares |
| Bruce Polsky Director | Jun 20, 2024 | 17,544 | $68.77K | Jun 20, 2024 | RESTRICTED STOCK |
| JPM Partners LLC Affiliate | Jun 5, 2024 | 1,006 | $4.02K | Jun 5, 2024 | Founder Shares |
| John Vavricka Chief Commercial Officer | Feb 1, 2024 | 13,552 | $55.16K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| Andrea Corcoran CFO, EVP, Legal and Secretary | Feb 1, 2024 | 18,198 | $74.07K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| Jean-Pierre Sommadossi President, CEO, and Chairman | Feb 1, 2024 | 65,476 | $266.49K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| Janet MJ Hammond Chief Development Officer | Feb 1, 2024 | 16,110 | $65.57K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| Wayne Foster EVP, Chief Accounting Officer | Feb 1, 2024 | 14,311 | $58.25K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| Maria Arantxa Horga Chief Medical Officer | Feb 1, 2024 | 18,227 | $74.18K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
See a number that looks wrong?